Therapiestudien zu Kopf-Hals-Karzinomen – Highlights der ASCO-Jahrestagung 2021

Zusammenfassung

Aktuell entwickeln sich die therapeutischen Möglichkeiten im Gebiet der Kopf-Hals-Onkologie, v. a. durch den Einsatz von Checkpoint-Inhibitoren, rasch weiter. Momentan werden zahlreiche Studien zur medikamentösen Therapie von Kopf-Hals-Karzinomen mit neuen molekularen Targets bzw. neuen Medikamentenkombinationen durchgeführt. Die wichtigsten Ergebnisse der Studien, die bei der ASCO-Jahrestagung 2021 zu Kopf-Hals-Karzinomen vorgestellt wurden, sollen in dieser Arbeit vorgestellt werden.

Abstract

The therapeutic options in head and neck oncology are rapidly developing, especially through the use of checkpoint inhibitors. Currently, numerous therapeutic studies with new molecular targets or new drug combinations are underway in patients with head and neck cancer. The most important results of the studies presented at the ASCO Annual Meeting 2021 on head and neck cancer will be presented in this paper.

Schlüsselwörter

ASCO - Kopf-Hals-Tumoren - Checkpoint-Inhibitoren - Chemotherapie

Key words

ASCO - head and neck cancer - checkpoint inhibitors - chemotherapy

Publication History

Article published online:
01 September 2021

• Literatur

• 1 Ma J, Chen YP, Sun Y. et al. Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial. J Clin Oncol 2021; 39 (Suppl. 15) 6003
• 2 Miao J, Wang L, Tan SH. et al. Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial. J Clin Oncol 2021; 39 (Suppl. 15) 6005
• 3 Fang W, Yang Y, Ma Y. et al. Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials. Lancet Oncol 2018; 19: 1338-1350
• 4 Zhang L, Yang Y, Qu S. et al. Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial. J Clin Oncol 2021; 39 (Suppl. 15) 6000
• 5 Yang Y, Qu S, Li J. et al Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncol 2021; 22 (08): S1470-2045(21)00302-8
• 6 Xu R, Mai HQ, Chen QY. et al. JUPITER-02: Randomized, double-blind, phase III study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC). J Clin Oncol 2021; 39 (Suppl. 15) LBA2
• 7 Uppaluri R, Zolkind P, Lin T. et al Neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2017; 35 (suppl.): abstr 6012
• 8 Uppaluri R, Chernock R, Mansour M. et al. Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2021; 39 (Suppl. 15) 6008
• 9 Wise-Draper TM, Takiar V, Mierzwa ML. et al. Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2021; 39 (Suppl. 15) 6006
• 10 Cohen EEW, Ferris RL, Psyrri A. et al. Primary results of the phase III JAVELIN head & neck 100 trial: Avelumab plus chemoradiotherapy (CRT) followed by avelumab maintenance vs CRT in patients with locally advanced squamous cell carcinoma of the head and neck (LA SCCHN). Ann Oncol 2020; 31 (Suppl. 04) S599-S628
• 11 Hecht M, Eckstein M, Rutzner S. et al. Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration. J Clin Oncol 2021; 39 (Suppl. 15) 6007
• 12 Kao HF, Liao BC, Huang YL. et al. Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis. J Clin Oncol 2021; 39 (Suppl. 15) 6024
• 13 Jackovich A, Gitlitz BJ, Wong Tiu-lim JM. et al. Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma. J Clin Oncol 2021; 39 (Suppl. 15) 6016
• 14 Brana I, Forster M, Lopez-Pousa A. et al. Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma. J Clin Oncol 2021; 39 (Suppl. 15) 6028
• 15 Chung CH, Saba NF, Steuer CE. et al. Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). J Clin Oncol 2021; 39 (Suppl. 15) 6017
• 16 Hanna GJ, O'Neill AM, Jo VY. et al. Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck. J Clin Oncol 2021; 39 (Suppl. 15) 6053
• 17 Ang KK, Harris J, Wheeler R. et al. Human papillomavirus and survival in head and neck cancer. N Engl J Med 2010; 363 (01) 24-35
• 18 Gillison ML, Trotti AM, Harris J. et al. Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial. Lancet 2019; 393: 40-50
• 19 Rischin D, King MT, Kenny LM. et al. Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study. J Clin Oncol 2021; 39 (Suppl. 15) 6012
• 20 Ferris RL, Flamand Y, Weinstein GS. et al. Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311). J Clin Oncol 2021; 39 (Suppl. 15) 6010
• 21 Rosenberg A, Agrawal N, Pearson AT. et al. Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial. J Clin Oncol 2021; 39 (Suppl. 15) 6011
• 22 Lee NY, Sherman EJ, Schöder H. et al. The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer. J Clin Oncol 2021; 39 (Suppl. 15) 6019